Regulatory Style Educational Brief

A. Persistent abdominal fat and body weight management

Retatrutide

Evidence type: Human phase 2 randomized, double blind, placebo controlled trial in adults with obesity. Retatrutide produced substantial body weight reductions over 48 weeks in the published trial.

Regulatory status: Investigational for obesity as of the cited publication.

AOD 9604 and HGH fragment 176 191

Evidence type: Literature includes preclinical work and mixed clinical development history for obesity. A review describes a 12 week randomized trial with modest weight change versus placebo and notes that development was terminated after a larger 24 week trial did not show significant weight loss.

Regulatory and safety context: FDA has noted limited safety related information for compounded drug products containing AOD 9604 and potential peptide related impurity characterization issues.

Preclinical example: GH and AOD 9604 effects on lipid metabolism and adiposity have been studied in obese mice.

5 Amino 1MQ

Evidence type: Primarily preclinical and mechanistic literature around inhibition of NNMT, with reported downstream effects such as reduced lipogenesis in adipocytes and altered NAD related cellular biochemistry in experimental systems.

SLU PP 332

Evidence type: Preclinical. Published work characterizes SLU PP 332 as a synthetic agonist of estrogen related receptors (ERR), studied as an “exercise mimetic” affecting muscle and metabolic function in vitro and in vivo. It is not described as a PPAR delta agonist in the cited primary research.

B. Low energy and mitochondrial support

MOTS c

Evidence type: Foundational preclinical and mechanistic work describing MOTS c as a mitochondrial derived peptide involved in metabolic homeostasis and AMPK related signaling.

SS 31 (elamipretide)

Evidence type: Human randomized, double blind, placebo controlled clinical trial experience exists in primary mitochondrial myopathy programs, with additional mechanistic rationale related to cardiolipin binding and mitochondrial function.

NAD and NAD boosting approaches

Evidence type: Human studies more commonly evaluate NAD precursors or NAD boosting combinations rather than direct NAD administration. For example, NRPT increased blood NAD in a randomized, placebo controlled study, and NMN increased blood NAD and was reported as generally well tolerated in a randomized trial.

Context: Reviews discuss NAD biology, aging associations, and the state of translational evidence.

NAD plus carnitine blend

Evidence type: The blend itself is not a single standardized molecule, so evidence must be assessed by ingredient and formulation. For carnitine alone, randomized trial meta analyses report modest average weight reduction in adults and discuss heterogeneity across studies.

C. Sleep quality

DSIP (delta sleep inducing peptide)

Evidence type: Human clinical literature exists, including an early open study and a double blind study in chronic insomnia evaluating sleep related outcomes.

CJC 1295 and Ipamorelin

Evidence type: CJC 1295 has human randomized, placebo controlled evidence showing sustained increases in GH and IGF 1 in healthy adults.

Regulatory and safety context: FDA has raised concerns about risks and limited clinical data for compounded drug products containing CJC 1295.

Ipamorelin evidence includes pharmacology studies and registered clinical trials in postoperative gastrointestinal recovery contexts, with at least one published proof of concept trial reporting tolerability but no significant efficacy signal on key endpoints.

D. Mental clarity, stress, and anxiety related research

Semax

Evidence type: Mechanistic and preclinical literature suggests involvement with neurotrophin pathways including BDNF and TrkB in experimental settings.

Selank

Evidence type: Published literature discusses anxiolytic like effects and interactions with GABA related systems, with statements referencing clinical experience in certain regions and additional mechanistic work.

Regulatory and compounding context in the United States: Selank acetate has appeared in FDA compounding related category updates, underscoring that regulatory status for compounding is actively evaluated.

E. Muscle recovery and GH axis research

Tesamorelin

Evidence type: FDA approved drug in the United States for reduction of excess abdominal fat in HIV associated lipodystrophy. FDA labeling describes the clinical trial program and safety information.

CJC 1295

Evidence type: Human randomized, placebo controlled studies demonstrate dose dependent increases in GH and IGF 1 in healthy adults.

IGF 1 LR3

Evidence note: IGF 1 is an established human hormone and recombinant human IGF 1 (mecasermin) is FDA approved for specific pediatric growth failure indications.

IGF 1 LR3 is a modified analog distinct from FDA approved mecasermin, and publicly indexed, high quality human clinical evidence for IGF 1 LR3 specifically is limited compared with approved IGF 1 therapies.

F. Joint pain and tissue repair research

BPC 157

Evidence type: The literature base is largely preclinical, with recent reviews discussing proposed mechanisms and noting the limited nature of controlled human safety and efficacy data.

TB 500 and thymosin beta 4 (TB4)

Evidence type: Thymosin beta 4 has been investigated for corneal epithelial healing and related ophthalmic indications, including clinical trial activity and published clinical evaluations.

Terminology note: “TB 500” is often marketed as thymosin beta 4 related in non regulated contexts, but product identity and comparability should not be assumed without validated characterization.

KPV

Evidence type: KPV, a tripeptide derived from alpha MSH, has been studied for anti inflammatory effects in cellular and gastrointestinal inflammation models, including published work on PepT1 mediated uptake and NF kB related signaling effects.

KLOW blend

Evidence note: A proprietary “blend” is not a defined single active substance in the scientific literature. Evidence should be demonstrated per exact composition, manufacturing controls, and clinical evaluation.

G. Hair and skin appearance research

GHK Cu

Evidence type: Reviews and cosmetic dermatology literature describe mechanistic rationale and discuss clinical studies of topical copper tripeptide formulations, including reported effects on dermal matrix markers in placebo controlled settings.

KLOW blend

Evidence note: As a blend, clinical evidence must be assessed for the exact composition. Publicly indexed trials for a proprietary “KLOW blend” are not readily identifiable without additional sponsor provided details.

H. Immune resilience research

Thymosin alpha 1 (thymalfasin)

Evidence type: Human clinical literature exists across immunology contexts. For example, a pilot trial in hemodialysis patients examined thymalfasin for prevention of COVID related outcomes, and meta analyses have reported mixed conclusions depending on included studies and populations.

KPV

See the KPV evidence summary above.

I. Libido and sexual function research

Bremelanotide (PT 141)

Evidence type: FDA approved drug in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women. FDA labeling describes the pivotal trial structure and safety information.

Regulatory summary publications also describe its approval and indication.

Melanotan II

Evidence type: Human research literature exists, including a double blind, placebo controlled crossover study in men with erectile dysfunction that reported erections in the absence of sexual stimulation and documented adverse effects.

Safety note: Non approved melanotan products in non regulated markets have been associated with clinical safety concerns in case reports and public health warnings.

Handling, preparation, and administration

This document does not provide instructions for reconstitution, sterile compounding, injection technique, or dosing.

Any preparation or administration of a sterile drug product must be performed by qualified personnel using validated procedures and appropriate regulatory standards. Improper sterility assurance can cause serious infections.

Combination use (stacking)

From a regulatory perspective, combining investigational compounds increases uncertainty because:

• Interaction risks are often not characterized in adequate human trials
• Safety signals may not be attributable to one ingredient
• Product quality, identity, and purity may vary outside regulated supply chains

Therefore, combinations should only be evaluated within ethically approved clinical research or under physician directed care consistent with local law and applicable regulatory guidance.

Frequently asked questions (regulatory phrasing)

Are peptides the same as anabolic steroids

No. Peptides are chains of amino acids. However, regulatory status and safety depend on the specific molecule, manufacturing controls, and clinical evidence.

Are these compounds “generally safe”

Safety cannot be generalized across compounds. Many peptides discussed here have limited controlled human safety data, and some are FDA approved only for narrow indications, as reflected in official labeling.

Does this document provide dosing

No. Dosing and administration are medical decisions and require licensed oversight.

Scientific literature context for peptides and related compounds

Scope and intended use

This document is provided for scientific and educational discussion of publicly available literature regarding peptides and related compounds. It is not product labeling, prescribing information, medical advice, or a recommendation to use any substance. Clinical decisions, if any, must be made by a licensed healthcare professional based on an individual assessment.

Many compounds discussed below are investigational or not approved for routine clinical use in various jurisdictions. Regulatory status varies by country and can change over time.

Important regulatory and safety notice

Do not interpret inclusion of a compound as evidence of safety, quality, or fitness for any purpose.

Parenteral administration requires medical oversight, validated sterile preparation, and appropriate pharmacovigilance. Improper sterility control can cause serious harm.

The United States FDA has specifically flagged certain peptides as potentially presenting significant safety risks when used in compounding, and notes limited safety related information for some of them, including AOD 9604 and CJC 1295.

The United States FDA labeling for approved drugs should be treated as the authoritative source for indications, contraindications, and adverse reactions for those products.

Final compliance statement

Peptides and related compounds are actively studied in biomedical research. However, they do not replace established foundations of health, including nutrition, physical training, and sleep. Clinical use should only occur where legally permitted and supported by robust evidence, appropriate quality standards, and professional supervision.